ALPHA: ALitretinoin versus PUVA in severe chronic HAnd eczema trial

View pages in this document

Alpha logoThe ALPHA trial compares Alitretinoin and PUVA therapy in patients aged 18 years and over with severe hand eczema which is not controlled on a daily (regular) basis with prescription steroid creams.



May 2017:

  1. Unfortunately East Surrey Hospital is no longer able to recruit to the ALPHA trial. However, many thanks to Dr Man and her team for all the hard work that they have done and continue to do so as their participants attend their ALPHA follow up visits.

April 2017:

  1. We now have 160 participants randomised on the ALPHA study- an amazing achievement, well done to all teams!

  2. The ALPHA study is now open to recruitment in Glasgow, Circle Nottingham and Aneurin Bevan (Newport)- welcome!

March 2017:

  1. Did you see ALPHA featured in the Yorkshire Evening Post? Please see a link here
  2. Welcome to Coventry and Warwickshire who are now open to recruitment!

BBC Look North (Yorkshire) features Dr Miriam Wittmann discussing the ALPHA trial - click the link ( to watch the full programme. Here's a shortened version of the video on the BBC Look North face book page:


For earlier news feed items please go here

Want to know more?

Alpha patient zone 4Alpha hospitalsAlpha potential investigators

If you can't find a hospital near you, please keep checking regularly as more hospitals will be added as they are opened to recruitment.

Contact us

Are you a hospital based clinician who would like to take part in the ALPHA trial?  

Are you a research active GP practice? Would you like to refer patients with severe chronic hand eczema to a local ALPHA participating hospital?

If so, please contact Victoria Goss, Senior Trial Coordinator for more details:

Victoria Goss
Senior Trial Coordinator
Tel: 0113 343 4317


Hand eczema, hand dermatitis, clinical trial, ALPHA, research, Alitretinoin, PUVA, GP, NHS, NIHR HTA

 Hands up web size


Pages in this document

  1. ALPHA: ALitretinoin versus PUVA in severe chronic HAnd eczema trial
  2. Earlier news from the ALPHA trial